LFB

Leader in France in the field of plasma-derived medicinal products, 6th player worldwide, LFB Group is also one of the leading European companies for the development of monoclonal antibodies and new-generation proteins based on biotechnologies.

Biopharmaceutical group, and a French state-owned company, LFB Group is dedicated to developing, manufacturing and marketing medicinal products for serious, and often rare diseases. R&D is key to the strategy of LFB Group. With a 2008 budget amounting to nearly 20% of the turnover, research projects concern both a number of developments in the field of plasma proteins, and the marketing of products based on biotechnologies, in essential therapeutic areas such as Immunology, Hemostasis, Intensive Care and Oncology.

LFB Group has been expanding internationally with different subsidiaries namely in Brazil, Germany and Great Britain. These subsidiaries allow LFB to market high-therapeutic potential plasma-derived medicinal products. By strenghening its collaborations, the LFB group is developing internationally thanks to its agreements with partners in Europe, North America and Asia. In 2008, LFB signed a important industrial agreement with the Dutch Fondation Sanquin.

Type:	SILVER
Address:	Siège social 3, avenue des Tropiques B.P. 305 - Les Ulis - 91958 Courtabœuf Cedex
Website:	www.lfb.fr
Phone:	+33 (0) 1 69 82 70 10
Fax:	+33 (0) 1 69 07 19 03